UNSPSC 51352002: Gestodene

This classification denotes a therapeutic progestin with the molecular formula C21H26O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1664P6E6MI, chemically known as 18,19-dinorpregna-4,15-dien-20-yn-3-one, 13-ethyl-17-hydroxy-, (17-alpha)- but generally known as gestodene, which bears US NIH Compound Identifier 43249. European Medicines Agency schedules Gestodene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07901MIG.

UNSPSC 51352002 Gestodene, a Commodity code, covers the procurement of this specific progestin-based contraceptive pharmaceutical product by state and local government entities, health agencies, and cooperative purchasing alliances for distribution through public health facilities, clinics, and medicaid programs. State and local buyers source gestodene primarily through multi-source generic pharmaceutical contracts established via cooperative purchasing vehicles, where the product is bundled with other generic pharmaceuticals and over-the-counter items under master agreements with manufacturers and authorized wholesalers. Issuing bodies include state health departments, multistate purchasing alliances, and local public health agencies that consolidate demand across participating jurisdictions to negotiate volume-based pricing and ensure supply chain compliance with FDA and Drug Supply Chain Security Act requirements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents a typical issuing body for this class of commodity.

The most recent activity centers on the Upper Midwest and Pacific Northwest, with MMCAP's January 2026 RFP (S1070000015802) serving Minnesota and Oregon. MMCAP issued this Request for Proposal on January 20, 2026, with responses due March 26, 2026, to establish multiple contracts for generic pharmaceuticals including gestodene, effective July 1, 2026. Vendors must supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and meet cGMP certification, DSCSA compliance, insurance requirements (including $5 million commercial general liability per occurrence), and flexible pricing models (flat price, net price formats, or WAC-minus structures). The RFP weights price competitiveness at 75 percent of the evaluation, with EDI capability, administrative fee compliance, and fixed pricing forming the remainder. Contract terms are two years for new vendors with optional extensions, and all products must possess at least one-year expiration dates from manufacture with a minimum six-month shelf life.